Outset Medical, Inc. (NASDAQ:OM) Receives Consensus Rating of “Moderate Buy” from Analysts

Outset Medical, Inc. (NASDAQ:OM) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $16.00.

A number of brokerages have commented on OM. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research report on Monday. Stifel Nicolaus set a $14.00 price objective on Outset Medical and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Royal Bank Of Canada dropped their target price on Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 11th. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, BTIG Research decreased their price objective on shares of Outset Medical from $39.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th.

Outset Medical Trading Down 2.6%

Shares of Outset Medical stock opened at $4.18 on Friday. The firm’s 50 day simple moving average is $9.35 and its two-hundred day simple moving average is $14.09. The firm has a market capitalization of $75.88 million, a price-to-earnings ratio of -0.32 and a beta of 2.03. Outset Medical has a 12-month low of $4.00 and a 12-month high of $25.35. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69.

Institutional Investors Weigh In On Outset Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. Ameritas Investment Partners Inc. acquired a new stake in Outset Medical in the 2nd quarter valued at $35,000. BNP Paribas Financial Markets grew its stake in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Outset Medical in the 2nd quarter worth $78,000. Finally, New York State Common Retirement Fund acquired a new position in Outset Medical during the second quarter worth $108,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.